免疫標記的應(yīng)用與評價-資料下載頁
2025-10-03 11:43本頁面
【導(dǎo)讀】未動員前外周血中CD34+細胞1～4%，因子、化療聯(lián)合細胞因子等的動員。淋巴細胞和NK細胞確定和定量分析。淋巴細胞分化增殖異常的信號。淋巴細胞與髓系細胞的鑒別。混合性白血病和未確定性(型)白血病的診斷。造血干細胞病變的信號。細胞標志CD3、CD4和CD8。穿表達在整個T細胞分化發(fā)育過程中。胞表面標志需經(jīng)歷一定的變化過程。血液，執(zhí)行免疫功能。T細胞總數(shù)的60%~70%，20%~30%，1%~3%，CD2是綿羊紅細胞受體和淋巴細胞功能相。CD5、CD7是T細胞白血病較特異的標記，也是髓系白血病時最常見的伴隨標記。CD15、CD45則是白細胞的共同標記抗體，主要用于淋巴細胞疾病的免疫分型。另外，80％～90％和95％以上的NK細胞。CD37、CD2、CDw75、CDw76相繼出現(xiàn)。裂原受體，上述B細胞抗原繼續(xù)存在。CD79仍可存在于胞質(zhì)中。而言，CDl9是特異性和敏感性最高的。細胞終末階段，分化為漿細胞時丟失。胞和近5％的骨髓細胞。于正常和惡性B細胞。CD20和CD22與CD19和CD24有相同的特。CD19的陽性而出現(xiàn)。一般來說，這類白血病患者
【正文】 loid leukaemia with inv(16)(p13q22) or t(16。16)(p13。q22)。 CBFb/MYH11 ? Cytochemistry ? Abnormal eosinophils are CAE +ve ? Immunophenotype ? Granulocytic and monocytic markers ? Coexpression of CD2 in blast population ? Prognosis ? Favourable Acute myeloid leukaemia with inv(16)(p13q22) or t(16。16)(p13。q22)。 CBFb/MYH11 Acute promyelocytic leukaemia ? AML with t(15。17)(q22。q12)。 PML/RARa and variants ? Characteristic morphology ? Associated with disseminated intravascular coagulation Acute promyelocytic leukaemia Acute promyelocytic leukaemia Acute promyelocytic leukaemia ? Immunophenotype ? CD33+ CD13+ ? HLADR and CD34 negative ? Coexpression of CD2 and CD9 ? Geics ? t(15。17)(q22。q12) ? Variants: t(11。17)(q23。q12) PLZF/RARa。 t(5。17)(q32。q12) NPM/RARa。 t(11。17)(q13。q12) NuMA/RARa Acute promyelocytic leukaemia Acute promyelocytic leukaemia ? Treatment ? Alltrans retinoic acid (ATRA) ? Arsenic for relapse cases ? RARa variants: resistant to ATRA ? Prognosis ? Favourable when treated optimally with ATRA followed by anthracyclines Acute myeloid leukaemia with 11q23 abnormalities ? Infant leukaemia ? Therapy related AML after exposure to DNA topoisomerase II inhibitors ? Acute monocytic and myelomonocytic leukaemia ? Associated with MLL rearrangement Acute myeloid leukaemia with multilineage dysplasia ? Following MDS or MDS/MPD ? Without antecedent MDS ? Dysplasia in ? 50% of cells in at least 2 lines ? Poor prognosis AML and MDS, therapy related ? Alkylating agent related ? Topoisomerase type II inhibitor related Acute myeloid leukaemia not otherwise categorized ? Equivalent to FAB classification ? AML minimally differentiated ? AML without maturation ? AML with maturation ? Acute myelomonocytic leukaemia ? Acute monoblastic and monocytic leukaemia ? Acute erythroid leukaemia ? Acute megakaryoblastic leukaemia ? Acute basophilic leukaemia ? Acute panmyelosis with myelofibrosis ? Myeloid sara AML without maturation Acute myeloid leukaemia with maturation Acute monocytic leukaemia Erythroleukaemia Acute leukaemia of ambiguous lineage ? Mixed myeloid and lymphoid characteristics ? Biclonal (two clones) ? Biphenotypic (two characteristics on same blast cell) 免疫標記的評價 ? 必須進行的工作 ? 檢測中的對照問題 (與細胞化學(xué)有類似 ) ? 協(xié)同 (共同 )表達問題 ? 篩選與快速檢測問題 ? 抗體選擇問題 ? 重復(fù)性和精確性檢測問題
教學(xué)課件相關(guān)推薦
鄂ICP備17016276號-1